c-kit+ cells

BIOLOGICAL2 trials

Sponsors

The University of Texas Health Science Center, Houston, Joshua M Hare

Conditions

Hypoplastic Left Heart SyndromeIschemic Cardiomyopathy

Phase 1

The CHILD Trial: Hypoplastic Left Heart Syndrome Study.

CompletedNCT03406884

Joshua M HareHypoplastic Left Heart Syndrome

Start: 2019-10-16End: 2024-07-01Updated: 2026-01-23

Phase 2

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

CompletedNCT02501811

The University of Texas Health Science Center, HoustonIschemic Cardiomyopathy

Start: 2015-10-31End: 2020-07-22Updated: 2021-04-26

Related Papers

Changes in Circulating Biomarkers in Patients With Ischemic Heart Failure After Treatment With Autologous Mesenchymal Stromal Cells and c-Kit-Positive Cardiac Cells, Alone or in Combination: Results From the Cardiovascular Cell Therapy Research Network CONCERT-HF Clinical Trial.

2026-04-20

Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial.

2025-11-19

Statistical modeling of extracellular vesicle cargo to predict clinical trial outcomes for hypoplastic left heart syndrome.

2023-09-212 citations

Abstract 15156: Statistical Modeling of Cardiac-Derived Progenitor Cell Extracellular Vesicles to Predict Clinical Trial Outcomes

Circulation2022-11-08

Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study).

2022-04-0813 citations

Extracellular volume-guided late gadolinium enhancement analysis for non-ischemic cardiomyopathy: The Women’s Interagency HIV Study

BMC Medical Imaging2021-07-272 citations

Abstract 14080: A Phase II Randomized, Double-blind, Controlled Trial of Combined Mesenchymal Stromal Cells and C-kit+ Cardiac Progenitor Cells in Ischemic Heart Failure: The CCTRN CONCERT-HF Trial

Circulation2020-11-121 citations

Dose-dependent improvement of cardiac function in a swine model of acute myocardial infarction after intracoronary administration of allogeneic heart-derived cells.

2019-05-3131 citations

Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit <sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)

Circulation Research2018-04-27100 citations